Answers are grounded in this paper and cite their sources.
Postmarketing safety signals for multicomponent medicines are usually assigned to a whole product, leaving unresolved which component chemistry should be reviewed first. We formulate this problem as chemical information modeling over a heterogeneous safety graph connecting Kampo formulas, crude-drug components, ingredients, protein targets, protein-protein interactions, and adverse-reaction terms. HerbPairIAM represents components, unordered component pairs, and adverse reactions as fixed target-centered graph profiles, then learns adverse-reaction-conditioned attention to score formula-reaction candidates and rank component-level review priorities. High-confidence formula-adverse reaction signals were curated from JADER and FAERS using a four-estimator disproportionality vote rule requiring at least three positive estimators and at least three coreports. In a leakage-controlled tested-universe benchmark containing 704 positives among 3965 candidate pairs, HerbPairIAM achieved an AUROC of 0.823 and an AUPRC of 0.517 across 30 matched folds, outperforming seven tabular and graph-based baselines. Ablations showed that the unordered pair branch and fixed graph-derived profiles drove the performance gain, and formula-held-out evaluation retained transfer to unseen formula compositions. Generalization was substantially weaker in the ADR-held-out setting, localizing the main transfer boundary to sparse adverse-reaction target annotation; the model is therefore more reliable for prioritizing within a represented adverse-reaction space than for cold-start adverse-reaction phenotypes. Calibration, review-threshold analysis, leave-one-component perturbation, and package-insert auditing linked high-scoring candidates to compound, target, and documentary evidence, with 192 of the top 500 tested nonsignal candidates supported by Japanese package inserts, an enrichment that attenuates after adverse-reaction-family matching and is best read as family level concentration of review candidates rather than within-family discrimination. Two compound-target structural follow-ups provided illustrative plausibility checks for selected compound-target axes rather than mechanistic or clinical-toxicity validation. The resulting scores are intended for safety-review triage and mechanism-focused follow-up, not for direct causal attribution of toxicity.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: